• Nurturing Ingenuity
  • Collaborating for Growth
    • Services & Labs
    • Digital Health
      • Data Research Center
      • Hadassah Accelerator
    • Business Initiatives
  • Licensing Technologies
  • About Us
  • For Researchers
  • News & Events
  • Contact
  • My Briefcase
What’s new at Hadasit
Filter by:
News Events Newsletters Articles
April 18, 2023

Gamida Cell receives FDA approval for blood cancer therapy, developed in collaboration with Prof. Amnon Peled, Hadassah

Israeli biotech company Gamida Cell has secured approval from the US Food and Drug Administration (FDA) for Omisirge (omidubicel-onlv), an allogeneic cell therapy. We extend our warmest congratulations to Gamida Cell on reaching this long waited and crucial milestone, which sets new treatment horizons for the cancer patients.
We congratulate Prof. Peled, the Head of The Goldyne Savad Institute of Gene Therapy, who had a fundamental role in the development of cord blood stem cell and NK expansion technology of Gamid Cell Ltd and supported the program since its initiation in 2006 through phase I/II and into Phase III clinical studies to FDA approval. 
 
Previous
Next
© 2023 Hadasit - Hadassah Technology Transfer. All Rights Reserved.
Site by PearlCom
  • Homepage
    • Nurturing Innovation
    • Licensing Technologies
    • Portfolio
    • Contact
  • Collaborating for Growth
    • Services & Labs
    • Digital Health
    • Data Research Center
    • Hadassah Accelerator
    • Business Initiatives
  • About Us
    • Team
    • Board of Directors
    • Portfolio
  • For Researchers
    • Invention submission
    • Protect your invention
    • Q&A
    • Forms
  • News & Events
    • News
    • Newsletters
    • Events
    • Articles
Site by PearlCom